Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular Care
Terumo Health Outcomes (THO) and Medis Medical Imaging have announced a strategic partnership in the United States to enhance cardiovascular care. The collaboration combines THO's ePRISM clinical decision support platform with Medis' Quantitative Flow Ratio (QFR) technology, a non-invasive software for assessing coronary physiology.
The partnership will pilot at selected clinical sites, using real-time electronic health records data. Medis QFR has shown promising results in the FAVOR trials, demonstrating a 34% reduction in major adverse cardiac events compared to standard procedures. The technology has received approval in Japan and is included in the 2024 ESC guidelines with a Class I recommendation.
The PIONEER IV trial, involving 2,540 patients, will evaluate the next-generation QFR technology's integration with THO's ePRISM platform.
Terumo Health Outcomes (THO) e Medis Medical Imaging hanno annunciato una partnership strategica negli Stati Uniti per migliorare la cura cardiovascolare. La collaborazione unisce la piattaforma di supporto decisionale clinico ePRISM di THO con la tecnologia Quantitative Flow Ratio (QFR) di Medis, un software non invasivo per la valutazione della fisiologia coronarica.
La partnership sarà avviata in alcuni siti clinici selezionati, utilizzando dati in tempo reale delle cartelle cliniche elettroniche. Il QFR di Medis ha mostrato risultati promettenti negli studi FAVOR, dimostrando una riduzione del 34% degli eventi cardiaci avversi maggiori rispetto alle procedure standard. La tecnologia ha ricevuto approvazione in Giappone ed è inclusa nelle linee guida ESC 2024 con una raccomandazione di Classe I.
Il trial PIONEER IV, che coinvolge 2.540 pazienti, valuterà l'integrazione della tecnologia QFR di nuova generazione con la piattaforma ePRISM di THO.
Terumo Health Outcomes (THO) y Medis Medical Imaging han anunciado una asociación estratégica en los Estados Unidos para mejorar la atención cardiovascular. La colaboración combina la plataforma de soporte de decisiones clínicas ePRISM de THO con la tecnología Quantitative Flow Ratio (QFR) de Medis, un software no invasivo para evaluar la fisiología coronaria.
La asociación se pilotará en sitios clínicos seleccionados, utilizando datos de registros electrónicos de salud en tiempo real. El QFR de Medis ha mostrado resultados prometedores en los ensayos FAVOR, demostrando una reducción del 34% en eventos cardíacos adversos mayores en comparación con los procedimientos estándar. La tecnología ha recibido aprobación en Japón y está incluida en las guías ESC 2024 con una recomendación de clase I.
El ensayo PIONEER IV, que involucra a 2,540 pacientes, evaluará la integración de la tecnología QFR de nueva generación con la plataforma ePRISM de THO.
테루모 헬스 아웃컴스 (THO)와 메디스 메디컬 이미징이 심혈관 치료 향상을 위해 미국에서 전략적 파트너십을 발표했습니다. 이 협력은 THO의 ePRISM 임상 의사결정 지원 플랫폼과 메디스의 비침습적 관상 동맥 생리학 평가 소프트웨어인 정량적 유량 비율(QFR) 기술을 결합합니다.
이 파트너십은 실시간 전자 건강 기록 데이터를 사용해 선정된 임상 사이트에서 파일럿 테스트를 실시합니다. 메디스 QFR은 FAVOR 시험에서 표준 절차와 비교하여 주요 심장 부작용 사건을 34% 줄이는 결과를 보여주었습니다. 이 기술은 일본에서 승인을 받았으며 2024 ESC 가이드라인에 클래스 I 권장 사항으로 포함되어 있습니다.
2,540명의 환자가 참여하는 PIONEER IV 시험은 THO의 ePRISM 플랫폼과 차세대 QFR 기술의 통합을 평가합니다.
Terumo Health Outcomes (THO) et Medis Medical Imaging ont annoncé un partenariat stratégique aux États-Unis pour améliorer les soins cardiovasculaires. La collaboration combine la plateforme de support à la décision clinique ePRISM de THO avec la technologie Quantitative Flow Ratio (QFR) de Medis, un logiciel non invasif pour évaluer la physiologie coronarienne.
Ce partenariat sera testé dans des sites cliniques sélectionnés, utilisant des données de dossiers de santé électroniques en temps réel. Le QFR de Medis a montré des résultats prometteurs dans les études FAVOR, démontrant une réduction de 34% des événements cardiaques indésirables majeurs par rapport aux procédures standard. La technologie a été approuvée au Japon et est incluse dans les directives ESC 2024 avec une recommandation de Classe I.
L'essai PIONEER IV, impliquant 2 540 patients, évaluera l'intégration de la technologie QFR de nouvelle génération avec la plateforme ePRISM de THO.
Terumo Health Outcomes (THO) und Medis Medical Imaging haben eine strategische Partnerschaft in den Vereinigten Staaten angekündigt, um die kardiovaskuläre Versorgung zu verbessern. Die Zusammenarbeit kombiniert die klinische Entscheidungsunterstützungsplattform ePRISM von THO mit der Quantitative Flow Ratio (QFR) Technologie von Medis, einer nicht-invasiven Software zur Beurteilung der koronaren Physiologie.
Die Partnerschaft wird an ausgewählten klinischen Standorten getestet und nutzt Echtzeitdaten aus elektronischen Gesundheitsakten. Medis QFR hat vielversprechende Ergebnisse bei den FAVOR-Studien gezeigt und eine Reduzierung von 34% an schwerwiegenden unerwünschten Herzereignissen im Vergleich zu Standardverfahren demonstriert. Die Technologie wurde in Japan genehmigt und ist in den ESC-Richtlinien 2024 mit einer Empfehlung der Klasse I enthalten.
Die PIONEER IV Studie, an der 2.540 Patienten teilnehmen, wird die Integration der next-generation QFR-Technologie mit der ePRISM-Plattform von THO bewerten.
- Partnership combines complementary technologies to enhance cardiovascular care delivery
- Medis QFR technology showed 34% reduction in major adverse cardiac events in clinical trials
- QFR technology received approval in Japan and Class I recommendation in 2024 ESC guidelines
- Technology eliminates need for invasive wire-based procedures, potentially increasing efficiency and safety
- None.
– Collaboration combines Terumo's ePRISM™ precision medicine software platform with Medis' QFR® technology –
THO's partnership with
More than 60 million people currently suffer from coronary artery disease (CAD) worldwide1. Percutaneous Coronary Intervention (PCI) is a common method for treatment and management of patients with CAD. As Medis QFR is an angiographic image-based approach, it eliminates the need for a more invasive wire-based approach in assessing coronary physiology. It is also capable of evaluating multiple areas from the same images versus the wire-based approach which is vessel- and often lesion-specific. This can potentially increase efficiency and safety while reducing procedure time.
The FAVOR trials, performed in the EU, have proven the efficacy of the Medis QFR solution in practical use during and after an interventional procedure. The FAVOR III China trial demonstrated a
"This collaboration underscores Terumo's commitment to building an innovative care operating system that not only improves clinical outcomes but also streamlines the entire care pathway," said Ryan Graver, Senior Divisional Vice President, THO. "By utilizing our ePRISM platform alongside Medis' QFR technology and TIS' devices, we are equipping clinicians with a comprehensive suite that enhances procedural efficiency and patient outcomes. Together, we are redefining what's possible in cardiovascular care."
"At Medis Medical Imaging, we are thrilled to partner with Terumo Health Outcomes to push the boundaries of cardiovascular imaging and decision support," said Maya Barley, CEO of Medis Medical Imaging. "This collaboration provides a comprehensive solution that enhances diagnostic accuracy and treatment planning. It highlights our dedication to improving patient care through innovation, working together with our worldwide network of partners."
THO is a division of TIS, which offers a portfolio of high-quality interventional devices that complement the predictive insights offered by the ePRISM platform. While ePRISM assists clinicians in identifying patient risk and optimizing treatment strategies, the advanced tools from TIS support procedural efficiency, contributing to improved patient outcomes. This combination assists clinicians to make more informed decisions, facilitating smoother procedures and potentially reducing hospital costs and recovery times.
1 Tijn P.J. Jansen et al., Assessing Microvascular Dysfunction in Angina with Unobstructed Coronary Arteries. JACC 2021. |
2 Xu B., Tu S., Song L., Jin Z., Yu B., Fu G., Zhou Y., Wang J., Chen Y., Pu J., et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): A multicentre, randomised, sham-controlled trial. Lancet. 2021;398:2149–2159. doi: 10.1016/S0140-6736(21)02248-0 |
About Terumo Health Outcomes
Combining best-in-class care pathway consulting services with proven, state-of-the-art ePRISM precision medicine software platform, Terumo Health Outcomes (www.terumohealthoutcomes.com), a division of Terumo Interventional Systems, partners with clinicians and hospitals to deliver enhanced patient outcomes and operational efficiencies. The predictive power of ePRISM allows Terumo to deliver innovative digital solutions, providing clinicians with comprehensive, predictive patient analytics and critical data to help support treatment at the point of care – ultimately lowering the cost of healthcare delivery.
About Terumo
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for over 100 years. Based in
About Medis Medical Imaging
For over 35 years, Medis has been providing innovative, robust and extensively validated tools to the medical community worldwide. The heritage and core values are based on this strong purpose of contributing to a healthier society by providing the right tools to cardiologists, radiologists, researchers, and industry partners. Medis' software is internationally appreciated due to its ease of use and its clinical outcome for the patients. At Medis, quality is key, all the products are developed and validated extensively to guarantee the highest quality, without compromise. They continuously focus on the creation of clinically relevant innovative software solutions in the cardiovascular imaging domain.
View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-health-outcomes-and-medis-medical-imaging-announce-strategic-partnership-to-enhance-cardiovascular-care-302316981.html
SOURCE Terumo Medical Corporation
FAQ
What is the purpose of the Terumo and Medis Medical Imaging partnership for TRUMY stock?
What are the clinical results of Medis QFR technology announced in December 2024?
How many patients will be involved in the PIONEER IV trial for TRUMY's new technology?
